Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids. (2024). SKIN The Journal of Cutaneous Medicine, 8(2), s397. https://doi.org/10.25251/skin.8.supp.397